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Phyllodes tumors are extremely uncommon neoplasms that are usually benign. Patients with
phyllodes tumors typically present with a well-circumscribed, painless, ﬁrm, and mobile mass
or nodule characterized by rapid growth in a short period of time. It is recommended that these
tumors be excised even though it may look as a ﬁbroademoma. Our patient presented with a
left nipple mass with rapid growth. The patient had been previously diagnosed with malignant
phyllodes tumor, which was excised with adequate margins, later presenting with an exophytic
mass extending from the nipple along with bloody discharge. The patient underwent a complete
mastectomy of the left breast without a lymph node dissection, and pathology revealed an
additional focus of intramammary myoepithelioma. The aim of this case report is increase
awareness of these tumors and their potentially unusual presentations to allow clinicians the
ability to recognize these neoplasms earlier as well as recognizing the need for better adjuvant
therapy.
& 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).A 34 year-old Asian woman with chief complaint of bloody
discharge from an exophytic nipple lesion presented to the
breast clinic three months postpartum. Her family history is
signiﬁcant for breast cancer in two of her maternal aunts;
she is herself status post-surgical excision of a left breast
malignant phyllodes tumor in 2009 with negative margins.
Physical examination revealed a left nipple that was
markedly distended and tender with a visible central nodule
covered with ﬁbrinous exudate. There were no palpable.08.001
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m (M. Schultzel).masses or lymphadenopathy bilaterally and the right breast
was unremarkable. A ﬁne needle aspiration (FNA) of the left
nipple revealed clusters of atypical spindle cells, consistent
with a recurrence of her known phyllodes tumor. An
ultrasound of the left breast revealed non-palpable nodules
in the 2 o'clock position. A punch biopsy was performed for
conﬁrmation, which showed a recurrent malignant phyl-
lodes tumor with up to 7 mitoses per 10 high-power ﬁelds.
Right breast and metastatic workups were negative for
further disease.
Surgical therapy consisted of a total mastectomy given the
large volume of tissue involved in the central aspect of the
left breast, including the nipple–areolar complex. Postsurgicalen access article under the CC BY-NC-ND license
Figure 1. Fungating tumor.
Figure 2. Fungating tumor.
31Fungating malignant phyllodes tumorpathology of the left breast revealed recurrent malignant
phyllodes tumor with 74 mitoses per 10 high power ﬁelds and
clear margins. The irregular mass protruding from the nipple
measured 2.8 cm from the deep margin. There was also a
separate focus of intramammary myoepithelioma with malig-
nant spindle cell stroma.
1. Introduction
Phyllodes tumors are rare breast tumors that occur with an
observed frequency of less than 1% [1,2,5,7–10,12,13,
15,16]. In 1838, Johannes Muller ﬁrst coined the term
cystosarcoma phyllodes because of the observed leaf-like
projections into the cystic spaces of the tumor; however,
the term is misleading because the majority of these tumors
are benign and these tumors are rarely cystic [2,6,8,12,17].
Per the World Health Organization (WHO), phyllodes tumor
is the most appropriate nomenclature [6,8,13]. Histologi-
cally, these tumors are classiﬁed into benign, borderline and
malignant [1–4,6–10,12,15,17]. This is based on mitotic
activity, degree of cellular atypia, presence of stromal
growth, the characteristics of the tumor margins and tumor
necrosis [2,5,7–10,16]. Tumor growth rate, symptom dura-
tion and age do not hold predictive signiﬁcance; a size of
over 10 cm, which deﬁnes a giant phyllodes tumor, has been
the subject of debate as to the prognostic value of size [6].
According to one study, histotype was an independent
prognostic factor, with a ﬁve year survival rate for benign
tumors of 95.7%, for borderline tumors of 73.7% and for
malignant tumors of 66.1% [6]. Malignant phyllodes tumors
are the most aggressive, representing about 20% of all
phyllodes tumors [5].
2. Discussion
Phyllodes tumors are composed of stromal and epithelial
elements bordered by mesenchymal cells; the stromal compo-
nent is thought to have the malignant potential [1,2,6,9]. One
presents usually as a well-circumscribed, painless, ﬁrm and
mobile mass or nodule that is characterized by rapid growth
over a short period of time [1,2,6,8,11–13]. The size can range
from 1 cm to greater than 40 cm, with a median of 4 cm, while
20% grow to greater than 10 cm [2,6,8]. The patient may
present with pain due to its weight or from impingement on
underlying nerves, and in some cases skin ulceration in larger
tumors [8,12,13,15]. Our patient had many of these complaints,
but in addition her mass protruded out of the nipple with
bloody discharge. Notably, the patient's mass underwent rapid
growth in the several days prior to her scheduled surgery
(Figures 1 and 2).
These generally benign tumors do not usually metastasize,
but they may grow aggressively and may recur locally. The
rarer malignant and borderline tumors are capable of local
recurrence and metastasis [1,2,6,8,9]. Local recurrence has
been found to correlate with age, a positive surgical stump,
stromal overgrowth, greater tumor size, malignancy, surgical
approach, mitotic activity, tumor necrosis and positive
surgical margins, the last of which is most signiﬁcant
[5,8,10,11]. Decreased local recurrence is associated with
negative margins, smaller dimensions, absent tumor necrosis
and benign histological classiﬁcation [11].Understandably, local recurrence is higher following
lumpectomy in undiagnosed cases of phyllodes tumor [14].
Inadequate surgical management is an important risk factor
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dropping signiﬁcantly when margins are 1 cm or greater
[6,8,10]. If a tumor becomes “giant” there is a greater
possibility of tumor penetration into surrounding breast
tissue, hence the recommendation for excision of not only
visible tumor but also all breast tissue to ensure no local
recurrence [6]. One study reported the local recurrence
rate following a margin-negative resection of a borderline
or malignant phyllodes tumor to be as high as 21% [3,5],
despite appropriate surgical management. Other sources
claim there is metastasis in 25–31% of malignant tumors;
however, phyllodes tumors only metastasize in 4% of cases
overall, and of these the majority of patients were found to
have had borderline or malignant phyllodes tumors [6,10].
Axillary metastasis is rare, but is associated with a poor
prognosis [6]. Recommended of metastasis includes adju-
vant chemotherapy, second line chemotherapy, clinical
trials and palliative local therapy if appropriate [8,11,16].
Hematologic spread may occur in as many as 22% of
malignant tumors [8]. Metastases consist solely of stromal
cells, which occur primarily in the lungs, but they may also
travel to the bones, heart, soft tissue, pleura and liver
[1,2,5,6,8,13,15]. Lymphatic metastasis is rare, and the
associated lymphadenopathy is a result of necrotic degrada-
tion [1]. One study shows stromal overgrowth to be asso-
ciated with spread, stating that 72% of tumors with stromal
overgrowth will metastasize and that local recurrence is
strongly linked with metastasis [3,5].
Phyllodes tumors lack pathognomonic signs on ultrasound
or mammography making histology necessary for diagnosis,
but magnetic resonance imaging (MRI) may reveal morpho-
logical changes typical of a phyllodes tumor [1,2,6]. On
ultrasound, phyllodes tumor may be characterized as a
hypoechoic solid lobulated nodule with deﬁned borders,
heterogeneous echotexture and a lack of microcalciﬁcations
with potential scattered cystic regions [2,6,8,7,14]. Mam-
mography may also reveal lobulated uncalciﬁed masses,
which are round and well-circumscribed [7]. A positron
emission tomography (PET) scan can be used as a staging
tool for phyllodes tumors. A PET scan may indicate malig-
nancy but has a limited value in the management of
phyllodes tumor [7]. Findings consistent with a phyllodes
tumor on MRI include leaf-like solid segments in blood-ﬁlled
cystic spaces, which are best visualized on subtraction MRI.
The sensitivity of FNA is as low as 70%, frequently showing
cytologic features similar to ﬁbroadenomas, whereas core
biopsy is an effective option with in some studies having
higher sensitivity [6,14].
Genetic data is widely available for phyllodes tumors.
A study of Asian patients compared the genetic makeup of
phyllodes tumors to their histologic grade: benign, borderline,
and malignant. They found that 29 genes are responsible for
matrix formation, cell adhesion, epidermis formation, and
cell proliferation [9]. The worse the histological grade, the
more chromosomal changes were noted [9]. Notably, HOXB13
expression was found to be associated with stromal hyper-
cellularity and atypia [9]. Malignant histological features have
been shown to correlate with over-expression of p53, c-kit,
epidermal growth factor receptor, HIF-1 alpha, c-myc, CD10,
nitric oxide synthase, heparin sulfate, and Ki-67 [9]. HOXB13
has been used prognostically to evaluate breast cancer
recurrence in women treated with tamoxifen for hormone-receptor positive breast cancer [9]. HOXB13 was up-regulated
in malignant phyllodes tumors by 2.77-fold compared to
borderline tumors and by 2.85-fold compared to benign
tumors [9]. HOXB13 was not signiﬁcantly different in expres-
sion between benign and borderline tumors, making it more
speciﬁc for malignancy [9]. Phyllodes tumors are also asso-
ciated with Li Fraumeni Syndrome which shares p53 germ line
mutations. This syndrome with high neoplastic risk has the
deﬁning characteristics of early-onset female breast cancer,
malignant phyllodes tumors, brain cancer, sarcoma, and
adrenocortical tumors. One large retrospective study of high
risk families found that all families with members having a
p53 mutation had at least one family member with a sarcoma,
breast, brain, or adrenocortical carcinoma [18].
Wide surgical excision is usually the treatment of choice,
with margins of 1–2 cm [1,2,8,10,11,13,15]. Mastectomy
should be considered for recurrent or giant tumors, or
tumors for which excision would create a poor cosmetic
outcome [2,6,10]. One study proposes a ‘wait-and-watch’
policy for cases with negative stromal overgrowth and for a
benign or borderline tumor as they have a local recurrence
rate of 23% [10]. Lymphadenectomy is recommended for
palpable lymph nodes, which are present in 10–20% of cases
[1,6,13]. Prophylactic axillary node dissection is not gen-
erally recommended because these tumors rarely travel to
axillary lymph nodes, but it is necessary if there are evident
pathologic lymph nodes [8,11,12].
Hormone therapy has been shown to be inadequate in the
treatment of phyllodes tumors; while they can express
estrogen and progesterone receptors, the stromal compo-
nents do not [1,5,6,8]. Although there is no clear evidence
of beneﬁt with adjuvant therapies, radiotherapy may be
considered for high-risk phyllodes tumor, including those
with positive margins, those with stromal overgrowth, or
those greater than 5 cm2. The treatment of choice for a
patient with positive margins is re-excision to obtain clear
margins. A retrospective study at the Shikoku Cancer Center
found that patients who had margin-negative resections in
addition to adjuvant radiotherapy and re-excision for posi-
tive margins had disease-free rates of 85%, 85% and 81%
after 5, 10 and 15 years, respectively. Thus, they recom-
mend this combination for borderline and malignant phyl-
lodes tumors as well a re-excision for positive margins [3].
Adjuvant chemotherapy has not been shown to have an
effect on mortality; however, studies have shown radio-
therapy to provide better local control [8,11,16].
3. Conclusion
Phyllodes tumors are rare neoplasms with low malignancy
potential. Targeted genetic therapy and radiotherapy may
hold promise in treating these tumors compared to other
adjuvant therapies; however, more research is necessary to
determine the best treatment option for patients with
malignant phyllodes tumors.
References
[1] M. Szrajda, R. Szyca, A. Jasiński, M. Gryz, K. Leksowski, A case
of a giant phyllodes tumour of the breast, Contemp. Oncol. 15
(2011) 44–46. http://dx.doi.org/10.5114/wo.2011.20531.
33Fungating malignant phyllodes tumor[2] J. Nabi, Q. Akhter, F. Authoy, A case of large phyllodes tumor
causing rupture of the breast: A unique presentation (Retrieved
from), Case Rep. Oncol. Med. 2013 (2013) 1–4. http://dx.doi.
org/10.1155/2013/871292.
[3] R.J. Barth Jr, W.A. Wells, S.E. Mitchell, B.F. Cole, A prospective,
multi-institutional study of adjuvant radiotherapy after resection
of malignant phyllodes tumors, Ann. Surg. Oncol. 16 (2009)
2288–2294. http://dx.doi.org/10.1245/s10434-009-0489-2.
[4] Y. Shin, S. Lee, K. Kim, M. Park, J. Kim, H. Yim, Y. Choi,
Collision tumor with inﬂammatory breast carcinoma and
malignant phyllodes tumor: a case report and literature review
(Retrieved from), World J. Surg. Oncol. 12 (2014).
[5] D. Jardim, A. Conley, V. Subbiah, Comprehensive character-
ization of malignant phyllodes tumor by whole genomic and
proteomic analysis: biological implications for targeted ther-
apy opportunities (Retrieved from), Orphanet J. Rare Dis. 8
(2013).
[6] M.I. Liang, B. Ramaswamy, C.C. Patterson, M.T. McKelvey,
G. Gordillo, G.J. Nuovo, W.E. III, Giant breast tumors: surgical
management of phyllodes tumors, potential for reconstructive
surgery and a review of literature, World J. Surg. Oncol. (2008)
6. http://dx.doi.org/10.1186/1477-7819-6-117.
[7] J. Chung, E.J. Son, J. Kim, E. Kim, J.Y. Kwak, J. Jeong, Giant
phyllodes tumors of the breast: imaging ﬁndings with clinico-
pathological correlation in 14 cases, Clin. Imag. 35 (2) (2011)
102–107. http://dx.doi.org/10.1016/j.clinimag.2010.01.004.
[8] P. Khosravi-Shahi, Management of non metastatic phyllodes tumors
of the breast: review of the literature, Surg. Oncol. – Oxf. 20
(2011) 143–148. http://dx.doi.org/10.1016/j.suronc.2011.04.007.
[9] M.K. Ang, A.S. Ooi, A.A. Thike, P. Tan, Z. Zhang, K. Dykema,
P.H. Tan, Molecular classiﬁcation of breast phyllodes tumors:
validation of the histologic grading scheme and insights into
malignant progression, Breast Cancer Res. Treat. 129 (2011)
319–329. http://dx.doi.org/10.1007/s10549-010-1204-5.
[10] N. Taira, D. Takabatake, K. Aogi, S. Ohsumi, S. Takashima,
R. Nishimura, N. Teramoto, Phyllodes tumor of the breast:
stromal overgrowth and histological classiﬁcation are useful
prognosis-predictive factors for local recurrence in patientswith a positive surgical margin, Jpn. J. Clin. Oncol. 37 (10)
(2007) 730–736. http://dx.doi.org/10.1093/jjco/hym099.
[11] G. Korpanty, D. Power, C. Murphy, M. Kell, J. McCaffrey,
Phyllodes tumor of the breast, Med. Oncol. 28 (2011) S62–S64.
http://dx.doi.org/10.1007/s12032-010-9695-9.
[12] M. Stamatakos, S. Tsaknaki, K. Kontzoglou, J. Gogas,
A. Kostakis, M. Saﬁoleas, Phylloides tumor of the breast: a
rare neoplasm, though not that innocent, Int. Semin. Surg.
Oncol. 6 (2009) 117–120. http://dx.doi.org/10.1186/1477-
7800-6-6.
[13] S. Prakash, P. Raj, A very large malignant phyllodes tumor with
skin ulceration and nipple areola complex involvement – still a
reality!!! Indian J. Surgery 75 (1) (2013) 39–42. http://dx.doi.
org/10.1007/s12262-012-0499-3.
[14] P. Ramakant, S. Chakravarthy, J. Cherian, D. Abraham,
M. Paul, Challenges in management of phyllodes tumors of
the breast: a retrospective analysis of 150 patients, Indian J.
Cancer 50 (4) (2013) 345–348. http://dx.doi.org/10.4103/
0019-509X.123625.
[15] S.A. Crenshaw, M.D. Roller, J.K. Chapman, Immediate breast
reconstruction with a saline implant and AlloDerm, following
removal of a phyllodes tumor, World J. Surg. Oncol. 9 (34)
(2011) 34–37. http://dx.doi.org/10.1186/1477-7819-9-34.
[16] I.H. Park, Y. Kwon, E. Kim, K.S. Lee, J. Ro, Major response to
sunitinib (Sutenes) in metastatic malignant phyllodes tumor
of breast, Investig. New Drugs 27 (2008) 387–388. http://dx.
doi.org/10.1007/s10637-008-9195-3.
[17] S. Macher-Goeppinger, F. Marme, B. Goeppert, R. Penzel,
P. Schirmacher, H.P. Sinn, S. Aulmann, Invasive ductal breast
cancer within a malignant phyllodes tumor: case report and
assessment of clonality, Hum. Pathol. 41 (2010) 293–296. http:
//dx.doi.org/10.1016/j.humpath.2009.08.006.
[18] K.D. Gonzalez, K.A. Noltner, C.H. Buzin, D. Gu, C.Y. Wen-Fong,
V.Q. Nguyen, J.H. Han, K. Lowstuter, J. Longmate, S.S. Sommer,
J.N. Weitzel, Beyond Li Fraumeni Syndrome: clinical character-
istics of families with p53 germline mutations, J. Clin. Oncol. 27
(8) (2009) 1250–1256.
